The ART BMC Plus features an integrated filter system for the ultrafiltration of proteins from platelet poor plasma. By injecting the plasma from one syringe on Port “B “to another syringe on Port “C” the cells are forced through the hundreds of hollow, nanoporous fibers, and water and salt ions are pushed out while proteins and cells are further concentrated. The fluid may be concentrated by passing through the filter until the desired volume is obtained. This ultrafiltration enriches the concentration of most proteins like Alpha-2 Macroglobulin (A2M), Interleukin-1 receptor antagonist protein (IRAP), VEGF, PDG-F, TGF-Beta, FGF and Fibrinogen1, 2, 3. A2M is a powerful natural plasma protease inhibitor, cytokine carrier, and ligand for cell-signaling receptors, which exists in two well-characterized conformations and is synthesized primarily in the liver but dispersed through the blood plasma in bone marrow and blood4. A2M stops the progression of Osteoarthritis (OA) by preventing degenerative cartilage breakdown and assisting with cartilage repair 4. In its plasma-soluble tetramer form, it encapsulates matrix metallo-proteinases (MMP’s) and other destructive enzymes common to arthritic tissue and slows or halts the breakdown of articular cartilage surfaces and other forms of the Extracellular Matrix (ECM)5. A2M also binds up pro-inflammatory molecules: TNF-a, TGF-b, and IL-1b 4.
Less inflammation = less pain
Less inflammation allows local cells to repair the Extracellular Matrix.
- Functionally closed system minimizes sterile breaks
- You can process anywhere from a minimum of 40 cc up to 60cc aspirate for a variety of applications
- Thumb-wheel allows for selective deconstruction of fluid stack and is designed to accommodate a wide variety of variability of the patient’s Hematocrit
- Adjustable flow valve diverts fluid without additional sterile breaks
- ART BMC Plus features integrated nanoporousfibers for filtering the platelet poor plasma tofurther concentrate cells
- Efficient concentration yields of ultra-low hematocrit
- Unmatched concentration of molecules, including fibrinogen, alpha-2 macroglobulin, and cytokines of similar molecular weights6
- Customized fluid fractions for tailored final product (e.g. BMC, fibrinogen, A2M, etc.)
- Eliminates turbulence by keeping buffy coat in the collection zone, can yield 3cc to 5cc on average of buffy coat from a typical 60cc bone marrow aspiration
- Consistently achieves high yields of mononuclear cells
- On average 60cc bone marrow aspirate will yield 25cc to 30cc of platelet poor plasma where further filtration will yield 3cc to 5cc on average of plasma; when combined with buffy coat it will result in 6cc to 10cc total volume available for injection
1 Murphy et al. Adult and umbilical cord blood-derived platelet-rich plasma for mesenchymal stem cell proliferation, chemotaxis, and cryo-preservation.Biomaterials 2012; 33(21):5308-5316.
2 Wang et al. Identification of alpha-2-macroblobulin as a master inhibitor of cartilage-degrading factors that attenuates the progression of posttraumaticosteoarthritis. Arthritis & Rheumatology 2014;66(7):1843-1853
3 Cassano et al. Bone marrow concentrate and platelet-rich plasma differ in cell distribution and interleukin 1 receptor antagonist protein concentration.Knee Surg Sports Tramatol Arthrosc, 1 Feb 2016.
4 AhmedA, et al. Alpha-2-Macroglobulin: A Physiological Guardian, Journal of cellular physiology, 2013 – Wiley
5 Sanja Arandjelovic, et al. A derivative of the plasma protease inhibitor α2-macroglobulin regulates the response to peripheral nerve injury,Journal of Neurochemistry, 11 July 2007
6 Data on File. Celling Biosciences, 2016.
7 Karli et al. “Autologous Regenerative Therapies: Rapid Concentration of Progenitor Cells, Platelets, and Proteins at the Point-of-Care,” TERMIS annual meeting, September 2015, Boston, MA.
8 Hegde et al. “A Prospective Comparison of 3 Approved Systems for Autologous Bone Marrow Concentration Demonstrated Nonequivalency in Progenitor Cell Number and Concentration,” J Ortho Trauma, Vol. 28, October 2014
9 Gassling V. et al. Clin Oral Implant Res 2013 Mar;24(3):320-8
*MSC may be reported as CFU-F or CTP